Societal Indicators Sample Clauses

Societal Indicators. The LMAPD also requires government to report annually on societal indicators of labour market participation of persons with disabilities. Societal indicators include: • employment rate; • education attainment; and • employment earnings.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Societal Indicators. The following information regarding societal indicators has been provided by Human Resources and Skills Development Canada and is based on information from data from Statistics Canada, Survey of Labour and Income Dynamics. For more information about the Survey of Labour and Income Dynamics, visit the Government of Canada Statistics Canada website at xxx.xxxxxxx.xx.
Sample 1Sample 2Sample 3See All (4)
Societal Indicators. Each year the Canada‐Nova Scotia Labour Market Agreement for Persons with Disabilities reports have included societal indicators using data from the Participation and Activity Limitation Survey (PALS), when available, and the Survey of Labour and Income Dynamics (SLID). Human Resources Skills Development provides the societal indicators data for the annual reports each September16. This report includes SLID data from 1999 thru 2010 for most of the societal indicators. The SLID is a longitudinal survey, interviewing the same panel of respondents each year over a period of six years. It tracks overlapping panels of individual respondents and is conducted annually. It is a rich source of information about income, employment, education and other characteristics of the adult Canadian population. Since the first report in 2004 there have been improvements on some of the societal indicators for persons with disabilities. There has been a steady increase in the educational achievements of working aged adults since 1999. There has been an increase in employment and a decrease in the proportions of persons with disabilities who do not participate in the labour force. As the economy grew between 2001 and 2009, the numbers of persons with disabilities who were able to participate in the labour force increased. Greater participation in the labour force was accompanied by increases in average annual incomes and greater numbers of persons with disabilities with earned income. The constant dollar value of average incomes for persons with disabilities has fluctuated year to year as it increased between 2001 and 2009. Over the same period, the constant dollar value of average incomes for persons who do not have a disability increased steadily from one year to the next. These two trends resulted in a decline in the average earnings (constant dollars) of persons with disabilities expressed as a percentage of the average earnings (constant dollars) of persons who do not have a disability. In 2010 the average earnings of persons with disabilities were equivalent to 85 percent of the average earnings of persons without a disability – 16 2009 was an exception. The data was delayed and subsequently reported in an updated release February 2010
Sample 1
Societal Indicators. The following charts represent societal indicators of labour market participation for Nova Scotians. These indicators include educational attainment, labour force activity and employment income. The source for the data is the Participation and Activity Limitation Xxxxxx (XXXX) 00000.
Sample 1
Societal Indicators. The following charts represent societal indicators of labour market participation for Nova Scotians. Indicators include: educational attainment, labour force activity and employment income. The 2004 baseline report presented societal indicators using data from the Participation and Activity Limitation Survey (PALS), Canada’s principal source of detailed statistical information about disability issues. PALS was first conducted in 2001 and it will be conducted again following the 2006 census. This year’s report uses another important Statistics Canada survey, the Survey of Labour and Income Dynamics (SLID), to present societal indicators. SLID is conducted annually and is a rich source of information about income, employment, education and other topics for the adult Canadian population. SLID tracks the same individuals over a period of years. The SLID data provides information about the education levels, employment earnings and trends within these measures for people with and without disabilities. Participation in the Labour Force Charts 1 and 2 show the level of participation and non-participation in the labour force by individuals aged 16 to 64. Individuals are considered employed only if they were employed for the entire year. Similarly, individuals unemployed or not active in the labour force experienced that employment status for the whole year. 1 There have been improvements in the percentage of persons with disabilities participating in the labour force over the seven year period 1999 to 2005. In 2005 47% of persons with disabilities were employed compared to 36% in 1999. Over the same period there was a 6% increase in the numbers of employed persons with out disabilities. People with out disabilities are more likely than persons who are disabled to participate in the labour force - this can be seen in the lower percentages of employed persons with disabilities (Chart 1) and the higher percentage of persons with disabilities who do not participate or are unemployed (Chart 2). Chart 1: % Employed 1999 – 2005 80 70 60 50 40 30 20 10 0 Disabled 1999 2000 2001 2002 2003 2004 2005 All Individuals Not Disabled Chart 2: % Unemployed or not in the labour force 1999 – 2005 80 70 60 50 40 30 20 10 0 1999 2000 2001 2002 2003 2004 2005 All Individuals Disabled Not Disabled
Sample 1

Related to Societal Indicators

  • Geographical Indications 1. Each Party shall recognise that geographical indications may be protected through a trade xxxx or sui generis system or other legal means in accordance with its laws and regulations.

  • Performance indicators and targets The purpose of the innovation performance indicators and targets is to assist the University and the Commonwealth in monitoring the University's progress against the Commonwealth's objectives and the University's strategies for innovation. The University will report principal performance information and aim to meet the innovation performance indicators and targets set out in the following tables.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Performance Indicators The HSP’s delivery of the Services will be measured by the following Indicators, Targets and where applicable Performance Standards. In the following table: n/a meanç ‘not-appIicabIe’, that there iç no defined Performance Standard for the indicator for the applicable year. tbd means a Target, and a Performance Standard, if applicable, will be determined during the applicable year. INDICATOR CATEGORY INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator 2019/20 PERFORMANCE TARGET STANDARD Organizational Health and Financial Indicators Debt Service Coverage Ratio (P) 1 c1 Total Margin (P) 0 cO Coordination and Access Indicators Percent Resident Days – Long Stay (E) n/a n/a Wait Time from LHIN Determination of Eligibility to LTC Home Response (M) n/a n/a Long-Term Care Home Refusal Rate (E) n/a n/a SCHEDULE D — PERFORMANCE 2/3 INDICATOR CATEGORY Quality and Resident Safety Indicators INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator Percentage of Residents Who Fell in the Last 30 days (M) 2019/20 PERFORMANCE TARGET STANDARD n/a n/a Percentage of Residents Whose Pressure Ulcer Worsened (M) n/a n/a Percentage of Residents on Antipsychotics Without a Diagnosis of Psychosis (M) n/a n/a Percentage of Residents in Daily Physical Restraints (M) n/a n/a SCHEDULE D — PERFORMANCE 2.0 LHIN-Specific Performance Obligations 3/3

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

Time is Money Join Law Insider Premium to draft better contracts faster.